^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Chronic Lymphocytic Leukemia
    Drug:Imbruvica (ibrutinib) (BTK inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A1 - Approval
    Source:
    European Medicines Agency
    Published date:
    10/21/2014
    Excerpt:
    Imbruvica as a single agent or in combination with rituximab or obinutuzumab is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL).
    Evidence Level:
    Sensitive: A1 - Approval
    New
    Source:
    FDA
    Excerpt:
    IMBRUVICA is a kinase inhibitor indicated for the treatment of adult patients with:...Chronic lymphocytic leukemia (CLL)/Small lymphocytic lymphoma (SLL)
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    Chronic lymphocytic leukemia/Small lymphocytic lymphoma...CLL/SLL without del(17p)/TP53 mutation…Second-line and subsequent therapy…Other recommended regimens…Ibrutinib (category 1)
    Evidence Level:
    Sensitive: B - Late Trials
    New
    Source:
    Am J Hematol
    Title:

    Outcomes with ibrutinib by line of therapy and post-ibrutinib discontinuation in patients with chronic lymphocytic leukemia: Phase 3 analysis

    Excerpt:
    ...ibrutinib was associated with favorable PFS and OS, and high ORR regardless of prior therapies in patients with CLL.
    DOI:
    10.1002/ajh.25436